Nyxoah ( (NYXH) ) just unveiled an update.
Nyxoah announced the release of its financial results for the fourth quarter and fiscal year 2024, scheduled for March 13, 2025. The company will host a conference call to discuss these results, reflecting its ongoing commitment to transparency and stakeholder engagement. This announcement underscores Nyxoah’s strategic focus on expanding its market presence and regulatory approvals, particularly in the U.S., where it seeks FDA approval for its Genio® system.
More about Nyxoah
Nyxoah is a medical technology company focused on developing innovative treatment alternatives for Obstructive Sleep Apnea (OSA) through neuromodulation. Their flagship product, Genio®, is a battery-free hypoglossal neuromodulation device designed to alleviate OSA symptoms. The company has achieved significant milestones, including CE Mark approval in Europe and successful IPOs on Euronext Brussels and NASDAQ.
YTD Price Performance: 10.76%
Average Trading Volume: 43,451
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $344.3M
Learn more about NYXH stock on TipRanks’ Stock Analysis page.